Market: NASD |
Currency: USD
Address: 2001 Market Street
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
📈 Context Therapeutics Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$5.20
-
Upside/Downside from Analyst Target:
504.65%
-
Broker Call:
12
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Context Therapeutics Inc.
| Date | Reported EPS |
|---|
| 2025-08-06 | -0.09 |
| 2025-05-07 | -0.05 |
| 2025-03-20 | - |
| 2024-11-06 | -0.22 |
| 2024-08-07 | -0.04 |
| 2024-05-08 | -0.23 |
| 2024-03-21 | -0.42 |
| 2023-11-09 | -0.37 |
| 2023-08-09 | -0.31 |
| 2023-05-10 | -0.4 |
| 2023-03-22 | -0.22 |
| 2022-11-09 | -0.24 |
| 2022-08-11 | -0.25 |
| 2022-05-11 | -0.22 |
| 2022-03-23 | -0.19 |
📰 Related News & Research
No related articles found for "context therapeutics".
